The Nonprescription Drugs Advisory Committee (NDAC) and Anesthetic & Analgesic Drug Products Advisory Committee (AADPAC) discusses Emergent BioSolutions’ supplemental New Drug Application, sNDA 208411/S-006 for NARCAN (naloxone hydrochloride) nasal spray, 4 mg/0.1 mL, proposed for nonprescription treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in a meeting being held on February 15 at 9 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
- Emergent Surges after Selling its Travel Health Business for $380 Million
- Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
- FDA Joint Committee Meeting
- Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023